Meiji Seika Pharma Co., Ltd.
Overview
Meiji Seika Pharma Co., Ltd., is a leading pharmaceutical company based in Japan, specializing in the development and marketing of pharmaceutical drugs. It is a subsidiary of Meiji Holdings Co., Ltd., focusing on providing innovative solutions in infectious disease treatment and central nervous system therapies.
Core services & business areas
Active pharmaceutical ingredients supplied
Substances Meiji Seika Pharma Co., Ltd. is evidenced to supply (US FDA Drug Master File or EU CEP). Open any ingredient to see its full supplier landscape, CAS number and patent status.
API / Drug Master Files
Meiji Seika Pharma Co., Ltd. holds 3 active (7 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.
- ME3183Active2018-11-21
- DAUNORUBICIN HYDROCHLORIDE (DRUG SUBSTANCE)Active1998-09-01
- DOXORUBICIN HYDROCHLORIDE DRUG SUBSTANCEActive1998-04-30
- ME1111 DRUG SUBSTANCEInactive2012-11-12
- ARBEKACIN FREE BASE DRUG SUBSTANCE (ME1100)Inactive2012-06-08
- ARBEKACIN SULFATE DRUG SUBSTANCEInactive2011-09-30
- CEFDITOREN PIVOXIL DRUG SUBSTANCEInactive2004-06-22
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Meiji Seika Pharma Co., Ltd. in our records. PharmaTek screens the full directory against live FDA enforcement data.
Is this Meiji Seika Pharma Co., Ltd.? Get in front of buyers actively sourcing.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.